Indication
Prevention of skeletal related events in multiple myeloma
Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells within the bone marrow. Read more about Prevention of skeletal related events in multiple myeloma
51 drugs 42 manufacturers
Drugs that treat it
Common Prevention of skeletal related events in multiple myeloma therapies.
ZOLEDRONIC ACID (zoledronic acid in mannitol and 0.9 % sodium chloride)
PAMIDRONATE DISODIUM
ZOLEDRONIC ACID
ZOLEDRONIC ACID
ZOLEDRONIC ACID (zoledronic acid in mannitol and 0.9 % sodium chloride)
ZOLEDRONIC ACID
ZOLEDRONIC ACID
ZOLEDRONIC ACID
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMultiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells within the bone marrow.
Malignant plasma cells disrupt normal bone remodeling by stimulating osteoclast-mediated bone resorption—frequently via upregulation of receptor activator of nuclear factor-?B ligand (RANKL)—while simultaneously suppressing osteoblastic bone formation.
This imbalance leads to progressive bone destruction, osteolytic lesions, and severe generalized bone loss throughout the skeletal system.
Prevention of skeletal-related events focuses on averting debilitating structural complications of this disease process, specifically pathologic fractures, spinal cord compression, and the necessity for radiation therapy or orthopedic surgery to manage compromised bone.
- mayoclinic.org
Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells within the bone marrow
- mdpi.com
Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells within the bone marrow Malignant plasma cells disrupt normal bone remodeling by stimulating osteoclast-mediated bone resorption—frequently via upregulation of receptor activator of nuclear factor-κB ligand (RANKL)—while simultaneously suppressing osteoblastic bone formation
- nih.gov
Malignant plasma cells disrupt normal bone remodeling by stimulating osteoclast-mediated bone resorption—frequently via upregulation of receptor activator of nuclear factor-κB ligand (RANKL)—while simultaneously suppressing osteoblastic bone formation This imbalance leads to progressive bone destruction, osteolytic lesions, and severe generalized bone loss throughout the skeletal system
- nih.gov
Malignant plasma cells disrupt normal bone remodeling by stimulating osteoclast-mediated bone resorption—frequently via upregulation of receptor activator of nuclear factor-κB ligand (RANKL)—while simultaneously suppressing osteoblastic bone formation This imbalance leads to progressive bone destruction, osteolytic lesions, and severe generalized bone loss throughout the skeletal system Prevention of skeletal-related events focuses on averting debilitating structural complications of this diseas...
- ehaweb.org
This imbalance leads to progressive bone destruction, osteolytic lesions, and severe generalized bone loss throughout the skeletal system
- nih.gov
Prevention of skeletal-related events focuses on averting debilitating structural complications of this disease process, specifically pathologic fractures, spinal cord compression, and the necessity for radiation therapy or orthopedic surgery to manage compromised bone
- ashpublications.org
Prevention of skeletal-related events focuses on averting debilitating structural complications of this disease process, specifically pathologic fractures, spinal cord compression, and the necessity for radiation therapy or orthopedic surgery to manage compromised bone
Personalize your experience
Follow Prevention of skeletal related events in multiple myeloma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.